SEC Form 4 · accession 0000875320-26-000237
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carmen Bozic
Officer — EVP and CMO
Period of report
Jun 18, 2026
Accepted (ET)
Jun 23, 2026 · 4:08 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 18, 2026 | S | 1,020 | $462.17 | D | 15,933 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.